États-Unis · Plateformes & données · Finviz

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Publié par Finviz · États-Unis il y a 11 h

Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO ® upon close and infliximab-abda in Q3 2027; Collaboration combines Samsung Bioepis’ biosim ...

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

À lire aussi

Why Did Bloom Energy Stock Jump 10% Today?

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Colorado homeowners face $7,000 to $20,700 HOA special assessments for hail-damaged roofs — or risk foreclosure

Morgan Stanley's Ariana Salvatore on U.S. midterms: Executive policy is the story for markets

Analyst sends big warning on gold and bitcoin amid U.S. midterms

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Partager

À lire aussi

Why Did Bloom Energy Stock Jump 10% Today?

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Colorado homeowners face $7,000 to $20,700 HOA special assessments for hail-damaged roofs — or risk foreclosure

Morgan Stanley's Ariana Salvatore on U.S. midterms: Executive policy is the story for markets

Analyst sends big warning on gold and bitcoin amid U.S. midterms